Kim Jin-soo (biologist)
Kim Jin-soo | |
|---|---|
| Born | May 29, 1964 |
| Alma mater | Seoul National University, University of Wisconsin-Madison |
| Awards | Highly Cited Researcher (2018–2019), Asan Award in Medicine (2017) |
| Scientific career | |
| Fields | ZFN, TALEN, CRISPR/Cas9 |
| Institutions | Howard Hughes Medical Institute, Massachusetts Institute of Technology, Samsung Biomedical Research Institute, ToolGen, Seoul National University, Institute for Basic Science |
| Korean name | |
| Hangul | 김진수 |
| Hanja | 金晋秀 |
| RR | Gim Jinsu |
| MR | Kim Chinsu |
| Website | Center for Genome Engineering |
Kim Jin-Soo (Korean: 김진수; born May 29, 1964) is a chemist, biologist, and entrepreneur. He was CEO and CSO, ToolGen, Inc., is a professor in the Department of Chemistry of Seoul National University and director of the Center for Genome Engineering. His research team has developed and improved several types of programmable nucleases, specifically zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), and RNA-guided engineered nucleases (RGENs). In 2018, he was a Clarivate Analytics Highly Cited Researcher in the cross-field category and in the biology and biochemistry category in 2019.